Adicet Bio, Inc.

ACET Healthcare Biotechnology

Adicet Bio, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $25.0 million.

EPS
+63.4%
Free cash flow
+24.9%

Quarter to June 2026, against a year earlier

3.05 0.13 +4.45%
Market cap
$27.3M
P/E
0.0×
Fwd P/E
−0.4×
Dividend yield
—
F-score
4/9
Altman Z
4.96
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
5.62 7.47 7.66 6.71
Net Debt/EBITDA
3.78 5.00 6.51 5.41
Debt/Equity
0.01 0.00 0.01 0.01
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(3.96) (3.03) (2.00) (1.86)
Book value per Share
19.17 23.10 13.04 11.18
Free Cash Flow
(22.52) (20.90) (21.53) (20.02)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates